{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:59:22Z","timestamp":1788472762592,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001321","name":"national research foundation","doi-asserted-by":"crossref","award":["NRF-2021R1F1A1060827"],"award-info":[{"award-number":["NRF-2021R1F1A1060827"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-024-02199-w","type":"journal-article","created":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T21:25:09Z","timestamp":1737926709000},"page":"393-401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reno-protective effects of xanthine oxidase inhibitors in patients with type 2 diabetes and chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"38","author":[{"given":"Chiwon","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Gyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-7135","authenticated-orcid":false,"given":"Jae Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12:2032\u20132045","journal-title":"Clin J Am Soc Nephrol"},{"key":"2199_CR2","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME (2014) Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 37:2864\u20132883","journal-title":"Diabetes Care"},{"key":"2199_CR3","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (2024) KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105:S117\u2013S314","journal-title":"Kidney Int"},{"key":"2199_CR4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825\u2013830","journal-title":"Ann Intern Med"},{"key":"2199_CR5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ekir.2022.11.016","volume":"8","author":"RJ Johnson","year":"2023","unstructured":"Johnson RJ, Sanchez Lozada LG, Lanaspa MA, Piani F, Borghi C (2023) Uric acid and chronic kidney disease: still more to do. Kidney Int Rep 8:229\u2013239","journal-title":"Kidney Int Rep"},{"key":"2199_CR6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T (2020) 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care Res (Hoboken) 72:744\u2013760","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2199_CR7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","volume":"76","author":"P Richette","year":"2017","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Liote F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T (2017) 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 76:29\u201342","journal-title":"Ann Rheum Dis"},{"key":"2199_CR8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1053\/j.ajkd.2022.04.006","volume":"80","author":"L Bathini","year":"2022","unstructured":"Bathini L, Garg AX, Sontrop JM, Weir MA, Blake PG, Dixon SN, McArthur E, Muanda FT (2022) Initiation dose of allopurinol and the risk of severe cutaneous reactions in older adults with CKD: a population-based cohort study. Am J Kidney Dis 80:730\u2013739","journal-title":"Am J Kidney Dis"},{"key":"2199_CR9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2165\/00003088-200645080-00005","volume":"45","author":"R Khosravan","year":"2006","unstructured":"Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L (2006) Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clin Pharmacokinet 45:821\u2013841","journal-title":"Clin Pharmacokinet"},{"key":"2199_CR10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00296-016-3612-2","volume":"37","author":"J Meng","year":"2017","unstructured":"Meng J, Li Y, Yuan X, Lu Y (2017) Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout. Rheumatol Int 37:299\u2013303","journal-title":"Rheumatol Int"},{"key":"2199_CR11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/s41598-020-57784-3","volume":"10","author":"T Nishikawa","year":"2020","unstructured":"Nishikawa T, Nagata N, Shimakami T, Shirakura T, Matsui C, Ni Y, Zhuge F, Xu L, Chen G, Nagashimada M, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S, Ota T (2020) Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice. Sci Rep 10:815","journal-title":"Sci Rep"},{"key":"2199_CR12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1159\/000516495","volume":"106","author":"EH Nadwa","year":"2021","unstructured":"Nadwa EH, Morcos GNB, Salama NM, Shafik AN (2021) Comparing the effects of febuxostat and allopurinol in an animal model of metabolic syndrome. Pharmacology 106:564\u2013572","journal-title":"Pharmacology"},{"key":"2199_CR13","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s10067-016-3474-8","volume":"36","author":"T Hosoya","year":"2017","unstructured":"Hosoya T, Sasaki T, Ohashi T (2017) Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumatol 36:649\u2013656","journal-title":"Clin Rheumatol"},{"key":"2199_CR14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s10157-014-0935-8","volume":"18","author":"T Hosoya","year":"2014","unstructured":"Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S (2014) Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin Exp Nephrol 18:876\u2013884","journal-title":"Clin Exp Nephrol"},{"key":"2199_CR15","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ejphar.2016.03.055","volume":"780","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Murase T, Nampei M, Morimoto N, Ashizawa N, Iwanaga T, Sakamoto R (2016) Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db\/db mice. Eur J Pharmacol 780:224\u2013231","journal-title":"Eur J Pharmacol"},{"key":"2199_CR16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1590\/2175-8239-jbn-2019-0091","volume":"42","author":"H Wen","year":"2020","unstructured":"Wen H, Yongling Z, Shuying Z, Jiali W, Yanling Z (2020) Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy. J Bras Nefrol 42:393\u2013399","journal-title":"J Bras Nefrol"},{"key":"2199_CR17","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s10157-018-1530-1","volume":"22","author":"T Wada","year":"2018","unstructured":"Wada T, Hosoya T, Honda D, Sakamoto R, Narita K, Sasaki T, Okui D, Kimura K (2018) Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study). Clin Exp Nephrol 22:860\u2013870","journal-title":"Clin Exp Nephrol"},{"key":"2199_CR18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y (2018) Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis 72:798\u2013810","journal-title":"Am J Kidney Dis"},{"key":"2199_CR19","doi-asserted-by":"crossref","first-page":"205435811667534","DOI":"10.1177\/2054358116675343","volume":"3","author":"S Beddhu","year":"2016","unstructured":"Beddhu S, Filipowicz R, Wang B, Wei G, Chen X, Roy AC, DuVall SL, Farrukh H, Habib AN, Bjordahl T, Simmons DL, Munger M, Stoddard G, Kohan DE, Greene T, Huang Y (2016) A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis 3:2054358116675343","journal-title":"Can J Kidney Health Dis"},{"key":"2199_CR20","first-page":"563","volume":"17","author":"MNA Mukri","year":"2018","unstructured":"Mukri MNA, Kong WY, Mustafar R, Shaharir SS, Shah SA, Abdul Gafor AH, Mohd R, Abdul Cader R, Kamaruzaman L (2018) Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial. Excli j 17:563\u2013575","journal-title":"Excli j"},{"key":"2199_CR21","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hrobjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"2199_CR22","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898","journal-title":"BMJ"},{"key":"2199_CR23","unstructured":"Higgins JPT LT, Deeks JJ (editors) (2024) Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) (ed) Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane"},{"key":"2199_CR24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61:991\u2013996","journal-title":"J Clin Epidemiol"},{"key":"2199_CR25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160","journal-title":"Evid Based Ment Health"},{"key":"2199_CR26","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-SAT-079","author":"F Satoh","year":"2019","unstructured":"Satoh F, Tezuka Y, Omata K, Ono Y, Shiratori B, Morimoto R, Kudo M, Ito S (2019) SAT-079 renal protective effects of topiroxostat and febuxostat in hypertensives with hyperuricemia. J Endocr Soc. https:\/\/doi.org\/10.1210\/js.2019-SAT-079","journal-title":"J Endocr Soc"},{"key":"2199_CR27","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10067-021-05956-5","volume":"41","author":"S Tsukamoto","year":"2022","unstructured":"Tsukamoto S, Okami N, Yamada T, Azushima K, Yamaji T, Kinguchi S, Uneda K, Kanaoka T, Wakui H, Tamura K (2022) Prevention of kidney function decline using uric acid-lowering therapy in chronic kidney disease patients: a systematic review and network meta-analysis. Clin Rheumatol 41:911\u2013919","journal-title":"Clin Rheumatol"},{"key":"2199_CR28","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu X, Qiu Y, Li D, Tan J, Liang X, Qin W (2021) Effectiveness of drug treatments for lowering uric acid on renal function in patients with chronic kidney disease and hyperuricemia: a network meta-analysis of randomized controlled trials. Front Pharmacol 12:690557","journal-title":"Front Pharmacol"},{"key":"2199_CR29","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, An K, Mou X, Zhang M, Su Q, Li S (2021) Effect of urate-lowering therapy on the progression of kidney function in patients with asymptomatic hyperuricemia: a systematic review and meta-analysis. Front Pharmacol 12:795082","journal-title":"Front Pharmacol"},{"key":"2199_CR30","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nefroe.2022.04.005","volume":"43","author":"PR Bignardi","year":"2023","unstructured":"Bignardi PR, Ido DH, Garcia FAL, Braga LM, Delfino VDA (2023) Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials. Nefrologia (Engl Ed) 43:167\u2013181","journal-title":"Nefrologia (Engl Ed)"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02199-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02199-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:07Z","timestamp":1777564447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/2\/393\/8307185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02199-w","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This article does not contain any studies with animals.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}]}}